Final Results and Notice of AGM
The Board of 4basebio plc is pleased to report the results for the financial year ended 31 December 2021.
The annual report and accounts together with a notice of the Company’s annual general meeting, which is to be held at 9:00 a.m. on Thursday, 9 June 2022 at The Cambridge Belfry, Back Lane, Great Cambourne, Cambourne, Cambridge CB23 6BW, are expected to be uploaded to the Company's website and posted to shareholders shortly.
The annual general meeting will be followed by a presentation from the Company through the Investor Meet Company platform on 13 June 2022 at 10am. Investors can sign up to Investor Meet Company for free and register interest here: https://www.investormeetcompany.com/4basebio-plc/register-investor.
Highlights
Admission to AIM
Commenced development of clean rooms for manufacture of DNA
Patents filings for hpDNA, osDNA and Hermes technologies
Evaluation Licence from muscular dystrophy vector
Joint Development Agreement with Leucid Bio
Strategic Research Collaboration with eTherRNA immunotherapies
4basebio PLC (formerly 4basebio UK Societas) is a holding and service company for the 4basebio group of companies and was spun out of 2Invest AG in 2020 and subsequently listed on AIM on 17 February 2021.
The Group is a specialist life sciences group of companies focused on supplying therapeutic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of these DNA/RNA based products to patients.
4basebio is now engaged in the development and manufacture of synthetic DNA and RNA products, targeted non-viral vector solutions and early stage AAV services. The Group’s near-term focus is the commercial supply of DNA and mRNA to partners for a range of gene therapy and vaccine applications, initially at research grade and in due course under GMP guidelines. 4basebio is also working to commercialise its targeted Hermes™ delivery technology across a range of indications and a breadth of tissue and cell types. It offers development services in addition to the development of its own portfolio of programs in conjunction with partners.
Dr Heikki Lanckriet, CEO and CSO for 4basebio, said: “4basebio operates in a rapidly expanding and exciting market, where we view the commercial opportunity for our synthetic DNA and Hermes™ technologies with increasing confidence. The significant progress made during to 2021 has led to our first DNA sales during 2022 and growing interest in our products from partners and prospective customers.”
For further enquiries, please contact:
4basebio PLC :Heikki Lanckriet, CEO +44 (0)12 2396 7943
Cairn Financial Advisers LLP (Nominated Adviser): Jo Turner / Sandy Jamieson+44 (0)20 7213 0880
finnCap Ltd (Broker): Geoff Nash/Richard Chambers/Charlotte Sutcliffe +44 (0)20 7220 0500